Skip to main content

Advertisement

SpringerLink
Log in

The effect of androgen deprivation therapy on body composition in men with prostate cancer: Systematic review and meta-analysis

  • Published:
Journal of Cancer Survivorship Aims and scope Submit manuscript

Abstract

Introduction

The use of androgen deprivation therapy (ADT) in the treatment of prostate cancer is associated with changes in body composition including increased fat and decreased lean mass. Limited information exists regarding the rate and extent of these changes. This systematic review was conducted to determine the effects of ADT on body composition in prostate cancer patients.

Methods

Literature searches were conducted on MEDLINE, EMBASE and Web of Science for studies until January 2009. Only longitudinal studies that examined ADT and body composition in prostate cancer patients were included. Data were extracted on body weight, BMI, percentage of fat mass and lean body mass.

Results

Sixteen studies (14 cohorts and 2 RCTs) met the inclusion criteria. Pooled data, calculated according to a random effects model, showed that ADT increased % body fat by on average 7.7% (95% CI 4.3, 11.2, from seven studies, P < 0.0001) and decreased % lean body mass by on average −2.8% (95% CI −3.6, −2.0, from six studies, P < 0.0001) but for both there was marked heterogeneity between studies (I2 = 99% I2 = 73%, respectively). Similarly, body weight (2.1%, P < 0.0001 from nine studies) and BMI (2.2%, P < 0.0001, from eight studies) increased significantly. More extensive changes were seen with longer duration of treatment.

Conclusions

Substantial increases in fat and declines in lean mass were observed in prostate cancer patients treated with ADT. Lifestyle changes or suitable interventions to minimize the effect of ADT on body composition need to be investigated.

Implications for cancer survivors

Prostate cancer survivors should be made aware of the side effect of treatment on body composition and further work is required to determine what interventions can minimize the impact of ADT on body composition and therefore what evidence based advice they should be provided with. In general, though recommendation of a healthy diet and moderate exercise is reasonable.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Demers RY, Tiwari A, Wei J, Weiss LK, Severson RK, Montie J. Trends in the utilization of androgen-deprivation therapy for patients with prostate carcinoma suggest an effect on mortality. Cancer. 2001;92:2309–17.

    Article  CAS  PubMed  Google Scholar 

  2. Hussain S, Gunnell D, Donovan J, McPhail S, Hamdy F, Neal D, et al. Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975–2004. BJU Int. 2008;101:547–55.

    Article  PubMed  Google Scholar 

  3. Gotkas S, Crawford ED. Optimal hormonal therapy for advanced prostatic carcinoma. Semin Oncol. 1999;26:162–73.

    Google Scholar 

  4. Morley JE. Testosterone and behavior. Clin Geriatr Med. 2003;19:605–16.

    Article  PubMed  Google Scholar 

  5. Vermeulen A, Goemaere S, Kaufman JM. Testosterone, body composition and aging. J Endocrinol Investig. 1999;22:110–6.

    CAS  Google Scholar 

  6. Herr HW, O’Sullivan M. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol. 2000;163:1743–6.

    Article  CAS  PubMed  Google Scholar 

  7. Stone P, Hardy J, Huddart R, A’Hern R, Richards M. fatigue in patients with prostate cancer receiving therapy. Eur J Cancer. 2000;36:1134–41.

    Article  CAS  PubMed  Google Scholar 

  8. Burton BT, Foster WR, Hirsch J, Van Itallie TB. Health implications of obesity: an NIH Consensus Development Conference. Int J Obes. 1985;9:155–70.

    CAS  PubMed  Google Scholar 

  9. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360:103–6.

    Article  CAS  PubMed  Google Scholar 

  10. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337:295–300.

    Article  CAS  PubMed  Google Scholar 

  11. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma–long-term results of phase III RTOG 85–31. Int J Radiat Oncol Biol Phys. 2003;61:1285–90.

    Google Scholar 

  12. Messing E, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer: results at 10 years of EST 3886. April 29, 2003; AUA Annual Meeting, Chicago, [Abstract #1480].

  13. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154–64.

    Article  CAS  PubMed  Google Scholar 

  14. Potter J, Langhorne P, Roberts M. Routine protein energy supplementation in adults: systematic review. BMJ. 1998;317:495–501.

    CAS  PubMed  Google Scholar 

  15. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range and the size of a sample. BMC Med Res Methodol. 2005;5:13.

    Article  PubMed  Google Scholar 

  16. Smith MR, Lee H, McGovem F, Fallon MA, Goode M, Zietman AL, et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer. 2008;112:2188–94.

    Article  CAS  PubMed  Google Scholar 

  17. Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol. 2004;22:2546–53.

    Article  CAS  PubMed  Google Scholar 

  18. Berruti A, Dogliotti L, Terrone C, Cerutti S, Isaia G, Tarabuzzi R, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol. 2002;167:2361–7.

    Article  PubMed  Google Scholar 

  19. Boxer RS, Kenny AM, Dowsett R, Taxel P. The effect of 6 months of androgen deprivation therapy on muscle and fat mass in older men with localized prostate cancer. Aging Male. 2005;8:207–12.

    Article  CAS  PubMed  Google Scholar 

  20. Denti L, Pasolini G, Cortellini P, Ferretti S, Sanfelici L, Ablondi F, et al. Effects of androgen suppression by gonadotropin-releasing hormone agonist and flutamide on lipid metabolism in men with prostate cancer: focus on lipoprotein(a). Clin Chem. 1996;42:1176–81.

    CAS  PubMed  Google Scholar 

  21. Galvao DA, Spry NA, Taaffe DR, Newton RU, Stanley J, Shannon T, et al. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int. 2008;102:44–7.

    Article  PubMed  Google Scholar 

  22. Lee H, McGovern K, Finkelstein JS, Smith MR. Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer. 2005;104:1633–7.

    Article  CAS  PubMed  Google Scholar 

  23. Nishiyama T, Ishizaki F, Anraku T, Shimura H, Takahashi K. The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J Clin Endocrinol Metab. 2005;90:657–60.

    Article  CAS  PubMed  Google Scholar 

  24. Nowicki M, Bryc W, Kokot F. Hormonal regulation of appetite and body mass in patients with advanced prostate cancer treated with combined androgen blockade. J Endocrinol Investig. 2001;24:31–6.

    CAS  Google Scholar 

  25. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab. 2001;86:4261–7.

    Article  CAS  PubMed  Google Scholar 

  26. Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology. 2004;63:742–5.

    Article  PubMed  Google Scholar 

  27. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Anne Fallon M, Schoenfeld DA, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87:599–603.

    Article  CAS  PubMed  Google Scholar 

  28. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006;91:1305–8.

    Article  CAS  PubMed  Google Scholar 

  29. Tayek JA, Heber D, Byerley LO, Steiner B, Rajfer J, Swerdloff RS. Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer. Metabolism. 1990;39:1314–9.

    Article  CAS  PubMed  Google Scholar 

  30. Sieber PR, Keiller DL, Kahnoski RJ, Gallo J, McFadden S. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol. 2004;171:2272–6.

    Article  CAS  PubMed  Google Scholar 

  31. Selly S, Donovan J, Faulkner A, Coast J, Gillatt D. Diagnosis, management and screening of early localised prostate cancer. Health Technol Assess. 1997;1(2):31–5.

    Google Scholar 

  32. Chen Z, Maricic M, Nguyen P, Ahmann FR, Bruhn R, Dalkin BL. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma. Cancer. 2002;95:2136–44.

    Article  PubMed  Google Scholar 

  33. Stoch SA, Parker RA, Chen L, Bubley G, Ko YJ, Vincelette A, et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab. 2001;86:2787–91.

    Article  CAS  PubMed  Google Scholar 

  34. van Londen GJ, Levy ME, Perera S, Nelson JB, Greenspan SL. Body composition changes during androgen deprivation therapy for prostate cancer: a 2-year prospective study. Crit Rev Oncol Hematol. 2008;68:172–7.

    Article  PubMed  Google Scholar 

  35. Basaria S, Leib J, Tang AM, DeWeese T, Carducci M, Eisenberger M, et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf). 2002;56:779–86.

    Article  CAS  Google Scholar 

  36. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab. 1999;84:2647–53.

    Article  CAS  PubMed  Google Scholar 

  37. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with nodepositive prostate cancer. N Engl J Med. 1999;341:1781–8.

    Article  CAS  PubMed  Google Scholar 

  38. Gong EM, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 2006;15:1977–83.

    Article  PubMed  Google Scholar 

  39. Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer. 2007;109:1192–202.

    Article  PubMed  Google Scholar 

  40. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, et al. Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85–31. Cancer. 2007;110:2691–9.

    Article  PubMed  Google Scholar 

  41. Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448–56.

    Article  CAS  PubMed  Google Scholar 

  42. Arrer E, Jungwirth A, Mack D, Frick J, Patsch W. Treatment of prostate cancer with gonadotropin-releasing hormone analogue: effect on lipoprotein[a]. J Clin Endocrinol Metab. 1996;81:2508–11.

    Article  CAS  PubMed  Google Scholar 

  43. Bassey EJ, Fiatarone MA, O’Neill EF, Kelly M, Evans WJ, Lipsitz LA. Leg extensor power and functional performance in very old men and women. Clin Sci (Lond). 1992;82:321–7.

    CAS  Google Scholar 

  44. Evans WJ. What is sarcopenia? J Gerontol A Bio Sci Med Sci. 1995;50:5–8.

    Google Scholar 

  45. Taaffe DR. Sarcopenia. Exercise as a treatment strategy. Aus Farm Physician. 2006;35:130–4.

    Google Scholar 

  46. Fiatarone MA, Marks EC, Ryan ND, Meredith CN, Lipsitz LA, Evans WJ. High-intensity strength training in nonagenarians. Effects on skeletal muscle. JAMA. 1990;263:3029–34.

    Article  CAS  PubMed  Google Scholar 

  47. Galvao DA, Nosaka K, Taaffe DR, Spry N, Kristjanson LJ, McGuigan MR, et al. Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc. 2006;38:2045–52.

    Article  PubMed  Google Scholar 

  48. Culos-Reed SN, Robinson JL, Lau H, O’Connor K, Keats MR. Benefits of a physical activity intervention for men with prostate cancer. J Sport Exerc Psychol. 2007;29:118–27.

    PubMed  Google Scholar 

  49. Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott CG, et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2003;21:1653–9.

    Article  PubMed  Google Scholar 

  50. See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol. 2002;168:429–35.

    Article  CAS  PubMed  Google Scholar 

  51. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of follow-up. J Urology. 2000;164:1579–82.

    Article  CAS  Google Scholar 

  52. Verhelst J, Denis L, Van Vliet P, Van Poppel H, Braeckman J, Van Cangh P, et al. Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer. Clin Endocrinol (Oxf). 1994;41:525–30.

    Article  CAS  Google Scholar 

  53. Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, et al. American Society of Clinical Oncology recommendations for the initial hormonalmanagementof androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol. 2004;22:2927–41.

    Article  PubMed  Google Scholar 

  54. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Baert L, Tammela T, et al. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology. 1998;51:389–96.

    Article  CAS  PubMed  Google Scholar 

  55. Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, et al. A randomised comparison of Casodex (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol. 1998;33:447–56.

    Article  CAS  PubMed  Google Scholar 

  56. Boccardo F, Rubagotti A, Barichello M, Battaglia M, Carmignani G, Comeri G, et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol. 1999;17:2027–38.

    CAS  PubMed  Google Scholar 

  57. Tyrrell CJ, Payne H, See WA, McLeod DG, Wirth MP, Iversen P, et al. Bicalutamide (Casodex) 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. Radiother Oncol. 2005;76:4–10.

    Article  CAS  PubMed  Google Scholar 

  58. Pietrobelli A, Heymsfield SB, Wang ZM, Gallagher D. Multi-component body composition models: recent advances and future directions. Eur J Clin Nutr. 2001;55:69–75.

    Article  CAS  PubMed  Google Scholar 

  59. Higgins JPT, Green S, editor. Cochrane handbook for systematic reviews of interventions. Version 5.0.2, Section 16.1.3.2, September 2009. Available from: http://www.cochrane-handbook.org/

Download references

Author information

Authors and Affiliations

  1. Cancer Epidemiology and Prevention Research Group, Centre for Public Health, Queen’s University Belfast, Belfast, Northern Ireland, UK

    Farhana Haseen, Liam J. Murray, Chris R. Cardwell & Marie M. Cantwell

  2. Centre for Cancer Research and Cell Biology, Queen’s University Belfast, and the Northern Ireland Cancer Center, Belfast, Northern Ireland, UK

    Joe M. O’Sullivan

  3. Queen’s University Belfast, Centre for Public Health, Mulhouse Building, Grosvenor Rd, Belfast, Northern Ireland, BT12 6BJ, UK

    Farhana Haseen

Authors
  1. Farhana Haseen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Liam J. Murray
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chris R. Cardwell
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joe M. O’Sullivan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marie M. Cantwell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Farhana Haseen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Haseen, F., Murray, L.J., Cardwell, C.R. et al. The effect of androgen deprivation therapy on body composition in men with prostate cancer: Systematic review and meta-analysis. J Cancer Surviv 4, 128–139 (2010). https://doi.org/10.1007/s11764-009-0114-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11764-009-0114-1

Keywords

Search

Navigation